Inthera bioscience

Author: mngo

August undefined, 2024

WebJun 26, 2024 · Funding. Inthera Bioscience has raised a total of $20.1M in funding over 3 rounds. Their latest funding was raised on Jun 26, 2024 from a Series A round. Inthera … WebApr 22, 2024 · DUBLIN, April 22, 2024 /PRNewswire/ -- The "Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.. Human ...

Pharmaceutical and Biopharmaceutical Contract Servicing

WebShe serves on the Board of Adenium Biotech. She serves as a Director of MinervaX, Avilex Pharma, Amakem NV, Pcovery ApS, ERA Biotech, Antag Therapeutics ApS and Complix NV. She has been a Director of Corwave SAS since November 2016. She has been a Director of Inthera Bioscience AG since May 31, 2024. WebScope. The scope of this joint Swiss Biotech Association & Swiss Academy of Engineering Sciences activity will be narrowed down to specific products and industrial processes using the suspension culture of prokaryotic and eukaryotic cells. Agricultural production methods, including PMP (plant-made pharmaceuticals), are not within the scope of ... how to make nextbots faster gmod

Inthera Bioscience Raises CHF 10.5 Million In Series A ... - BioSpace

WebPrivate Company. "Inthera is tackling “undruggable” targets with innovative chemistry for the design of small molecule inhibitors of intracellular protein-protein interactions. The most … WebMay 31, 2024 · Inthera Bioscience has raised €9.6M in Series A to complete preclinical phase of its lead cancer program and expand its pipeline. Inthera Bioscience, located in … WebKlaus Schollmeier is currently an advisor to the Pharma/Biotech industry and member of the board of several Biotech companies. Mr Schollmeier was Chief Executive Officer of SuppreMol, Munich/Germany from 2013 until 2015, when the company was sold to Baxalta. Prior to that, he served as CEO of Santhera, Basel/Switzerland, from 2004 to 2011 and … how to make new zip folder

Inthera Bioscience - Overview, News & Competitors - ZoomInfo

Web3105 Background: In advanced prostate cancer, the paralog transcription co-activators p300/CBP are often highly expressed and have been associated with disease … WebJun 28, 2024 · “Inthera Bioscience employs a proprietary technology platform to rationally design small molecule inhibitors of intracellular protein-protein interactions (PPIs).” Their approach involves first identifying key … mta iol white to whiteWebJun 1, 2024 · Inthera Bioscience is a private biopharmaceutical company focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary … mta internship deadline

"WebApr 30, 2014 · Inthera Bioscience General Information. Description. Developer of targeted small molecule therapies designed to treat solid tumors. The company's therapies are … " - Inthera bioscience

Inthera bioscience

Swiss Biotech raises €10M to Target Elusive Protein Interactions in …

WebDec 15, 2015 · Inthera Bioscience, a Zürich, Switzerland-based biopharmaceutical company focused on the development of small molecule therapies for solid tumors, raised $3.7m (€3.4m) seed funding round. WebLaRive Bio AG. LaRive Bio is a clinical development and licensing organization founded in 2024 and based in Zug. We seek to identify, license in/acquire, develop and license out …

Did you know?

WebTop Inthera Bioscience AG Employees Martin Bonde CEO. Copenhagen, DK View. 3 vaccibody.com; natimmune.dk; epitherapeutics.dk; 5+ +45 20 25 3XXXX +45 70 22 3XXXX +47 22 95 8XXXX +45 33 78 0XXXX +45 39 17 9XXXX +45 70 22 3XXXX; View Similar Profiles. How It ... WebMay 31, 2024 · Inthera Bioscience has raised €9.6M in Series A to complete preclinical phase of its lead cancer program and expand its pipeline. Inthera Bioscience, located in Zurich, has closed a €9.6M (CHF 10.5M) Series A round led by Merck Ventures and backed by Novo Seeds and BioMedical Ventures, as well as a private investor.Members of Novo …

WebJun 26, 2024 · Inthera Bioscience is a biopharmaceitical company developing first-in-class targeted small molecule therapies for solid tumors. The company’s drug discovery … WebInthera Bioscience AG. Inthera Bioscience AG operates as a biotech company. The Company develops and discovers medicines and drugs for the treatment of diseases. …

WebPrior to joining Inthera Bioscience he was Chief Development Officer at 4SC AG, a German clinical stage oncology company and TopoTarget A/S, a Danish clinical stage … WebFind the latest Interpace Biosciences, Inc. (IDXG) stock quote, history, news and other vital information to help you with your stock trading and investing.

WebAs an example of an early-stage company, Aukera, a project developing an mTOR drug discovery platform, sought further support and managed to get first contacts with experienced professionals at the event. Thereafter the CEOs of three Start- Up show-cases (Resistell, Inthera Bioscience and AOT – Advanced Osteotomy Tools) presented their …

WebFrom 2009-2024, they held various positions as CFO and Financial Advisor at Neurokey, Gubra, Lactobio, Octarine, Inthera Bioscience AG, Pephexia Therapeutics ApS, and Asgard Therapeutics. Jan's roles included assisting the Management team and Board in financial affairs such as financing, management reporting, budgetting, forecasting, … how to make next and previous button in htmlWebDec 15, 2015 · Inthera Bioscience, a Zürich, Switzerland-based biopharmaceutical company focused on the development of small molecule therapies for solid tumors, … mta insurance benefitsWebAug 4, 2024 · She now serves on the Boards of Epsilon-3 Bio, Glinova AB, Inthera Bioscience AG, ObsEva SA, and Orphazyme. From 2008-to 2012, she was an Associate with Apposite Capital, a London-based venture fund, where she was part of the life science investment team and participated in both primary and secondary investments, with … how to make nextbot